A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

• Status: Recruiting
• Trial end date: 2022-12-31

Summary

This Is a Multicenter, Randomized, Open-Label, Parallel-Group, Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents, and Young Adults with Relapsed or Refractory Osteosarcoma.

• Phase: Phase 2

Details

• Lead Sponsor: Eisai Inc.
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard; Lenvatinib